aha.org31m
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
Hosted on MSN2m
Non-Opioid Pain Medication Journavx Gets FDA Approval
providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA approval, the agency ...
JD Supra2m
FDA Bans Red Dye No. 3 in Food and Ingested Drugs: What Manufacturers Should Know
On January 16, 2025, the Food and Drug Administration (FDA) issued an order banning FD&C Red No.3 in food and ingested drugs.1 Food and ingested ...
aha.org33m
CISA, FDA warn of vulnerabilities in Contec patient monitors
The Cybersecurity and Infrastructure Security Agency and Food and Drug Administration Jan. 30 released notices warning of ...
Hosted on MSN23m
New type of non-opioid pain medication approved by FDA
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...
OHSU says no changes to gender-affirming care despite Trump executive order
President Donald Trump’s order aimed at limiting services for transgender youth could cut off federal funding but it’s ...
Asian News International on MSN57m
Cotecna Life Sciences India Inaugurates New Laboratory in Mumbai
Cotecna Life Sciences India Private Limited, formerly Geo-Chem Pharma, is proud to announce the inauguration of its new, ...
Chocolate recall reaches ‘highest risk level:’ products sold in 9 states
Three chocolate products have been recalled due to the presence of an undeclared allergen, the Food and Drug Administration ...
About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...
MIT Technology Review10m
Now read the rest of The Spark
The Chinese firm has pulled back the curtain to expose how the top labs may be building their next-generation models. Now things get interesting. What will really matter in the long run? That’s the ...